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481 How long can TIVADS be left unﬂushed?
B. Govin1, H. Miller1, C. Cowperthwaite1, P. Dyce1, M.J. Ledson1,
M.J. Walshaw1. 1Regional Adult CF Unit, The Cardiothoracic Centre, Liverpool,
United Kingdom
Introduction: Although manufacturers recommend that unused totally implanted
central venous access devices (TIVADS) are ﬂushed with heparin solution monthly,
this is not evidence based and frequent access increases the risk of infection, can
prematurely wear the membrane, and has resource complications. We have shown
that heparin remains active in the device at 2 months and routine ﬂushing can be
safely extended to this interval. However, the longest time that TIVADS can be
left unﬂushed is unclear. To address this, we looked at the complication rate in CF
patients with TIVADS attending our adult unit who had defaulted from their regular
ﬂush (<60 days).
Method: We reviewed 69 patient records of over 3 years (2005–2007), looking for
complications in those with extended ﬂush intervals.
Results: Fifty ﬁve (80%) received ﬂushes as recommended. The remaining 14
(20%) defaulted on 24 occasions (mean 128 days, range 77 to 298; 5 [36%]
>1 occasion [range 2−5]). In these, 10 TIVADS still function without complication,
despite 1 not being ﬂushed for 10 months. In the remaining 4, 1 developed infection,
1 had port migration, and 2 had clot formation (SVC obstruction and TIVAD
occlusion respectively). In the patient with SVC obstruction this was not temporally
related to the extended ﬂush interval. In the patient with occlusion, following TIVAD
removal and insertion of a new device, the subsequent TIVAD also became occluded
despite vigilant routine ﬂushing.
Conclusion: Our audit identiﬁed 24 episodes in 14 patients who had lengthened
ﬂush intervals, in some cases extremely prolonged. Although 4 suffered complica-
tions, in only 1 was this possibly related to the lack of routine ﬂushing. Further
studies are indicated to investigate the optimum time interval for routine ﬂushing
of TIVADS.
482 Central vein obstruction due to TIVADs: treatment in one
CF centre
N. Sinnott1, S. Baird1, M. Asim1, M.J. Ledson1, M.J. Walshaw1. 1Regional Adult
CF Unit, The Cardiothoracic Centre, Liverpool, United Kingdom
Introduction: Port occlusion and infection are well recognized complications of
totally implanted venous access devices (TIVADs), but associated thrombosis of
the great vessels is uncommon and there is no accepted treatment protocol: we
could ﬁnd only 5 examples in the CF literature. We therefore reviewed such cases
in patients attending our large regional CF centre.
Methods: We looked at demographics, presentation, management, outcome, any
complications and follow-up in all 5 patients (4 female) 1995 to 2007 with TIVADs
(all PortaCaths®) who had suffered a central venous thrombosis.
Results: Average age at thrombosis was 21 years (range 14−22), at a mean time
after implantation of 37 months (1−72). One catheter had migrated. 3 patients
presented with a swollen face and neck, 1 with arm pain and 1 with neck pain.
Three were investigated by MRI, 1 by venogram and 1 by venacavagram. All
underwent thrombolysis: 3 with streptokinase, 1 with alteplase and 1 with r-tpa.
Three different streptokinase regimes were used (1.5mu over 12 hours, 250,000 units
over 30min followed by 100,000 u/hr for 5 days, and 250,000u over 30min followed
by 100,000u/hr for 12 hours), all followed by heparin. One developed haemoptysis
(but no anaemia) and thrombolysis was stopped, and a further patient developed
bleeding from a venepuncture site and bruised arms. All 5 were commenced on
warfarin, but 2 had persistent symptoms. At follow up, in 4 patients the TIVAD
remained patent, but the 1 where the catheter had migrated was removed.
Conclusion: Each patient was managed differently, reﬂecting the lack of published
data. Collection of cases of this rare complication from different CF centres may
allow the development of guidelines to determine the best way of preserving central
veins in these patients.
483 Effects of pregnancy on the health of women with CF
S. Madge1, P. Agent1, G. Thorpe-Beeston2. 1Royal Brompton Hospital, London,
United Kingdom; 2Chelsea & Westminster Hospital, London, United Kingdom
Introduction: Health status is associated with maternal outcome following preg-
nancy. Pre-conception advice is based on lung function and nutritional status.
Aim: To review the health status of women with CF pre and post pregnancy 2000–
2007.
Methods: Records of women referred from this Centre to Chelsea and Westminster
Hospital for obstetric care were reviewed. Lung function and weight were recorded
one year pre-conception and approximately one year post delivery.
Results: Twenty-seven women (29 babies) were referred, data were collected on 26.
Mean age of mothers at delivery: 31 yrs (range 22−40 yrs). Genotype: homozygous
DF508 ×7, DF508/another mutation ×6, DF508/unknown mutation ×8, one known
and one unknown mutation ×2, no known mutations ×4. Sputum: Pseudomonas
aeruginosa +/− Staphylococcus aureus ×23. CF-related diabetes ×3, gestational di-
abetes ×6. Pre-pregnancy mean FEV1: 2.01 L (64% predicted, range 0.65−3.35 L),
mean FVC: 3.1 L (86.17% predicted, range 1.37−4.26 L), mean Sa02: 97.65% (93–
100%). Lung function one year post delivery – mean FEV1: 1.85 L (60% predicted,
range 0.65−3.27 L), mean FVC: 2.88 L (81% predicted, range 1.37−4.3 L), mean
Sa02: 97.28% (range 91–100%). Percent predicted change in FEV1: p< 0.05,
percent predicted change in FVC: NS. Mean pre-pregnancy weight: 65 kg (range
53−98 kg), post-pregnancy: 59.6 kg (range 49−76.6 kg). Change in weight: p = 0.03.
Discussion: Although these are small numbers, as with previous reports we
have found that declining health status is an indicator of outcome following
pregnancy (FEV1 and weight). With improving health and survival many young
women with CF expect to have children. It is essential that CF Teams use pre-
conception discussions to emphasise the importance of maximising health status
before conceiving, even in moderate disease.
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As patients with CF are living longer new issues arise, with increased co-morbidity
from both CF-related complications and conditions unrelated to CF. Surgery and
anaesthesia pose particular problems for these patients. We reviewed the surgical
procedures which our adult CF patients had required.
The records of 257 patients (146 male; age range 15−60 years) were reviewed.
Overall, 128 (50%) of these patients had undergone 250 full surgical procedures
under anaesthesia (not including gastrostomy or portacath insertion). Of all proce-
dures 65% were for conditions related to CF. There were 68 abdominal operations
including 20 laparotomies for meconium ileus, 10 for later bowel obstruction, 8
cholecystectomy, 2 fundoplication and 2 ﬁbrosing colonopathy operations. Fifty
ENT procedures were performed. Other procedures included 8 renal calculus
surgery, 4 lobectomies, 2 pneumothorax surgery, and 1 pulmonary embolectomy.
Twenty-ﬁve patients underwent lung transplant surgery. Surgery for conditions not
directly related to CF totalled 87 procedures. Gastrointestinal surgery included
5 appendicectomies, 5 hernia repairs and 1 colectomy for pseudomembranous
colitis. Nine gynaecological surgical procedures were performed and 6 patients
had a caesarean section. Other surgery included 10 orthopaedic, 2 vascular and 2
neurosurgical procedures. Eight patients required surgery for malignancy: 3 cervical
carcinoma, 2 skin cancer, 1 meningioma, 1 breast and 1 oesophageal carcinoma.
Patients with CF are undergoing an increasing range and complexity of surgical
procedures. A CF Centre needs to have close links with associated specialist
departments, and surgeons and anaesthetists need to be aware of the perioperative
management of CF.
